Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

Silas Inman @silasinman
Published: Monday, Feb 05, 2018

Maha H. Hussain, MB ChB
Maha H. Hussain, MB ChB
Treatment with the combination of enzalutamide (Xtandi) and androgen deprivation therapy (ADT) reduced the risk of metastases or death by 71% compared with ADT alone for patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to findings from the phase III PROSPER trial released ahead of the 2018 Genitourinary Cancers Symposium.

In the double-blind study, the median metastasis-free survival (MFS) was 36.6 months with enzalutamide plus ADT versus 14.7 months with ADT alone (HR, 0.29; 95% Ci, 0.24-0.35; P <.0001). Based on the promising findings, Pfizer and Astellas, the companies developing the antiandrogen agent, have already submitted a supplemental new drug application to the FDA.

“In the PROSPER trial, treatment with enzalutamide plus ADT delayed the development of metastases compared to standard-of-care ADT alone and, if approved, may provide men with nonmetastatic CRPC an important new treatment option,” lead investigator Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, said in a statement.

In the phase III PROSPER trial, 1401 patients with asymptomatic M0 CRPC were randomized to receive ADT plus enzalutamide at 160 mg daily (n = 933) or a matching sugar pill placebo (n = 468). ADT consisted of a gonadotropin-releasing hormone agonist/antagonist. All patients in the study had testosterone levels of ≤50 ng/dL, a prostate-specific antigen (PSA) doubling time of ≤10 months, and a PSA of ≥ 2 ng/mL. 

The primary endpoint of the study was MFS within 112 days of treatment discontinuation. Secondary endpoints of the study focused on PSA, time to next antineoplastic therapy, and overall survival (OS). Median duration of treatment with enzalutamide was 18.4 months compared with 11.1 months for the placebo group.

There was a 93% reduction in the risk of PSA progression in the enzalutamide arm compared with ADT alone (HR, 0.07; 95% CI, 0.05-0.08; P <.0001). The median time to PSA progression in the enzalutamide group was 37.2 months compared with 3.9 months for ADT alone.

The time to next antineoplastic therapy was extended by a median of 21.9 months with enzalutamide versus ADT alone. Men enrolled in the enzalutamide arm required a new therapy after a median of 39.6 months compared with 17.7 months in the placebo group, representing a 79% reduction in the risk of requiring a new therapy (HR, 0.21; 95% CI, 0.17-0.26; P <.0001).

The initial results from the PROSPER trial were available 2 years earlier than estimates, which predicted data maturation in 2020. At the time of the analysis, OS data were not yet mature, with medians unavailable for each arm. At this early stage, however, there was a trend toward improvement in OS with the addition of enzalutamide (HR, 0.80; 95% CI, 0.06-1.09; P = .1519).

There were significantly more adverse events (AEs) in the enzalutamide group compared with placebo (87% vs 77%). Grade ≥3 AEs were experienced by 31% of men in the enzalutamide arm compared with 23% of those in the placebo group. The grade ≥3 AEs that were more common in the enzalutamide group versus placebo, respectively, were hypertension (5% vs 2%) and fatigue (3% vs 1%).

AEs led to treatment discontinuation for 9% of patients in the enzalutamide arm compared with 6% in the placebo group. Five percent of patients in the enzalutamide arm experienced major cardiovascular events compared with 3% in the ADT alone arm. There were 3 seizures reported in the enzalutamide arm compared with none in the placebo group.

The FDA initially approved enzalutamide as a treatment for men with metastatic CRPC following docetaxel in 2012. This approval was expanded to include treatment with the antiandrogen prior to chemotherapy in 2014. If approved based on data from the PROSPER trial, the treatment would become the first approved therapy for patients with M0 CRPC.

“In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer," said Hussain, an OncLive Giant of Cancer Care in Genitourinary Cancer. "There are currently no approved systemic therapies for patients with non-metastatic CRPC in the United States.”
Hussain M, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2018;36 (suppl 6S; abstr 3).


<<< View more from the 2018 GU Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x